Journals / Pamukkale Tıp Dergisi / 2019 / Cilt: 12 - Sayı: 1

Insertion / deletion polymorphism of angiotensin-converting enzyme gene in ovarian hyperstimulation syndrome patients

Ovaryan hiperstimulasyon sendromlu hastalarda anjiotensin dönüştürücü enzim geni insersiyon / delesyon polimorfizmi

Pages
13–22
Publication Date
2022-10-19
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

ACE gene polymorphism doesn’t play a major role in the pathogenesis of OHSS.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: Previous studies have shown that ovary contains all the components of renin-angiotensin system.
📊
Key Findings & Data:Materials and methods: 47 patients who have undergone controlled ovarian hyperstimulation cycle (control n: 25; OHSS n: 22) were recruited in the study.
💡
Conclusion & Impact:ACE gene polymorphism doesn’t play a major role in the pathogenesis of OHSS.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Purpose: Previous studies have shown that ovary contains all the components of renin-angiotensin system. Renin-angiotensin system may play a primary role in the pathogenesis of ovarian hyperstimulation syndrome (OHSS). In this study our purpose was to investigate the relationship between the angiotensin-converting enzyme (ACE) gene insertion / deletion polymorphism and OHSS, in high risk patients for the syndrome. Materials and methods: 47 patients who have undergone controlled ovarian hyperstimulation cycle (control n: 25; OHSS n: 22) were recruited in the study. Estradiol levels of all patients in both group were higher than 3000 pg/ml . Age, duration of infertility, total gonadotropin dose, induction time, total follicular number, endometrial thickness and cause of infertility were recorded. DNA was extracted, and the insertion/deletion polymorphism of ACE gene was detected by polymerase chain reaction (PCR). Results: There were no statistically difference in age, duration of infertility, total gonadotropin dose, induction time and endometrial thickness between control and OHSS group. Follicle number was higher in OHSS group (p0.05). Homozygotes for the deletion polymorphism (DD genotype) were found 1.47 times higher in OHSS group (OR: 1.47 %95 confidence interval, 0.44 - 4.86) but this was statistically insignificant. Conclusion: These data indicate that ACE gene I/D polymorphism is not associated with OHSS. ACE gene polymorphism doesn’t play a major role in the pathogenesis of OHSS.

Özet

Amaç: Ovaryan hiperstimulasyon sendromu (OHSS) riski altındaki hastalarda, anjiotensin dönüştürücü enzim (ACE) gen insersiyon / delesyon (I/D) polimorfiziminin ovaryan hiperstimulasyon sendromu gelişiminde etkisinin olup olmadığının belirlenmesidir. Gereç ve yöntem: Yardımcı üreme teknikleri tedavisi için ovulasyon indüksiyon programına alınan, ve insan koryonik gonadotropin (hCG) yapıldığı gün östradiol seviyesi 3000 pg/ml’den fazla olan, OHSS gelişimi için yüksek risk altında bulunan 47 infertil hasta dahil edildi. Hastaların yaşı, infertilite süresi, kullanılan total gonadotropin dozu, indüksiyon süresi, elde edilen folikül sayısı, endometriyum kalınlığı ve infertilite nedeni kaydedildi. Kontrol (n:25) ve OHSS (n:22) grubu hastalarının ACE genine ait insersiyon/delesyon polimorfizmi, PCR yöntemiyle çalışılarak tesbit edildi. Bulgular: Yaş, infertilite süresi, gonadotropin dozu, indüksiyon süresi, endometriyum kalınlık ölçümleri iki grup arasında anlamlı farklılık göstermedi. Folikül sayısı kontrol grubunda 17.1 ± 4.2 OHSS grubunda 25.4 ± 6.8 olarak bulundu. Her iki grup arasında bulunan fark anlamlıdır (p0.05). OHSS grubunda genotipin DD olma olasılığı, kontrol grubuna gore 1,47 kat daha yüksektir (OR: 1.47 %95 Güven Sınırı, 0.44-4.86) fakat istatistiksel olarak anlamlı değildir. Sonuç: Çalışmada OHSS için yüksek riskli hastalarda ACE gen insersiyon/delesyon polimorfizmi çalışılmıştır. DD genotipinin oranı OHSS ve kontrol grubunda farklı değildir. ACE gen insersiyon/delesyon polimorfizmi, OHSS gelişiminde etken faktör olarak değerlendirilmemiştir.

🔖

Cite This Article

VARDAR, G., KABUKÇU, C. (2022). Insertion / deletion polymorphism of angiotensin-converting enzyme gene in ovarian hyperstimulation syndrome patients. Pamukkale Tıp Dergisi, Cilt: 12 - Sayı: 1, 13–22. https://ajindex.com/articles/587138

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Delvigne A, Rozenberg S. Review of clinical course and treatment of ovarian hyperstimulation syndrome (OHSS). Hum Reprod Update 2003;9:77-96
  2. Kumar P, Sait SF, Sharma A, Kumar M. Ovarian hyperstimulation syndrome. J Hum Reprod Sci 2011;4:70-75
  3. Schenker JG, Weinstein D. Ovarian hyperstimulation syndrome: a current survey. Fertil Steril 1978;30:255- 268
  4. Golan A, Ron-el R, Herman A, Soffer Y, Weinraub Z, Caspi E. Ovarian hyperstimulation syndrome: an update review. Obstet Gynecol Surv 1989;44:430-440
  5. Golan A, Weissman A. Symposium: Update on prediction and management of OHSS. a modern classification of OHSS. Reprod Biomed Online 2009;19:28-32
  6. Jenkins, JM, Drakeley AJ, Mathur RS. The management of ovarian hyperstimulation syndrome. In: Green-top guideline no
  7. London: Royal College of Obstetricians and Gynecologists 2006. reconfirmed 2016. Available at: https://www.rcog.org.uk/globalassets/documents/ guidelines/green-top-guidelines/gtg_5_ohss.pdf. Erişim tarihi 19 Nisan 2018
  8. Navot D, Bergh PA, Laufer N. Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatment. Fertil Steril 1992;58:249- 261
  9. McElhinney B, McClure N. Ovarian hyperstimulation syndrome. Baillieres Best Pract Res Clin Obstet Gynaecol 2000;14:103-122
  10. Humaidan P, Nelson SM, Devroey P, et al. Ovarian hyperstimulation syndrome: review and new classification criteria for reporting in clinical trials. Hum Reprod 2016;31:1997-2004
  11. Yarali H, Fleige-Zahradka BG, Yuen BH, McComb PF. The ascites in the ovarian hyperstimulation syndrome does not originate from the ovary. Fertil Steril 1993;59:657-661
  12. Alataş E. Ovaryan hiperstimulasyon sendromu ve sitokinler. Pamukkale Üniversitesi Tıp Fakültesi Dergisi 1999;5:26-33
  13. Field SL, Dasgupta T, Cummings M, Orsi NM. Cytokines in ovarian folliculogenesis, oocyte maturation and luteinisation. Mol Reprod Dev 2014;81:284-314. doi: 10.1002/mrd.22285 13. Pietrowski D, Szabo L, Sator M, Just A, Egarter C. Ovarian hyperstimulation syndrome is correlated with a reduction of soluble VEGF receptor protein level and a higher amount of VEGF-A. Hum Reprod 2012;27:196- 199. doi: 10.1093/humrep/der349 14. Soares SR, Gómez R, Simón C, García-Velasco JA, Pellicer A. Targeting the vascular endothelial growth factor system to prevent ovarian hyperstimulation syndrome. Hum Reprod Update 2008;14:321-333
  14. Kwik M, Maxwell E. Pathophysiology, treatment and prevention of ovarian hyperstimulation syndrom